Pejman Mansouri

Dr. Pejman Mansouri


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2017 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SMSeyed Mohammad Javad Mortazavi
Seyed Mohammad Javad Mortazavi
MFM. A. Firoozabadi
M. A. Firoozabadi
ANA. Najafi
A. Najafi
PMPejman Mansouri
Pejman Mansouri

18 September 2023 in Clinical Cardiology
Verified
Journal Article
Open access
MMMohammad Hadi Mansouri
Mohammad Hadi Mansouri
PMPejman Mansouri
Pejman Mansouri
MSMasoumeh Sadeghi
Masoumeh Sadeghi
SHSeyedeh Melika Hashemi
Seyedeh Melika Hashemi
AKAlireza Khosravi
Alireza Khosravi
NSNizal Sarrafzadegan
Nizal Sarrafzadegan
Introduction: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are emerging antidiabetic agents with various potential cardiovascular benefits. The EMPT‐ANGINA trial examined the effect of empagliflozin on the angina burden in those with concurrent type 2 diabetes mellitus (T2DM) and refractory angina (RA).Method: In this 8‐week, double‐blind, randomized, placebo‐controlled trial, 75 patients with T2DM and RA were randomly assigned to one of two groups: empagliflozin (n = 37) and placebo (n = 38). The primary outcome was an improvement in angina, which was assessed by the Seattle Angina Questionnaire (SAQ). The secondary outcomes of this study included alterations in the SAQ domains and exercise test components.Results: The mean age of individuals in the empagliflozin and placebo groups was 67.46 ± 9.4 and 65.47 ± 7.0 years, respectively (p = .304). Patients who received empagliflozin showed a significant improvement in both the primary endpoint, which was the SAQ Summary Score (192.73 ± 20.70 vs. 224 ± 25.36, p < .001) and the secondary endpoints. Exercise test components, including treadmill exercise duration, time till angina, 1 mm ST‐segment depression onset, and heart rate (HR) recovery, were all significantly improved in the empagliflozin group. This positive impact was reached with no clinically significant changes in resting and exertion HR or blood pressure. There were no significant side effects in the empagliflozin group (p = .125).Conclusion: Empagliflozin can be safely added as a metabolic modulator agent to existing antianginal medications in individuals with concurrent T2DM and RA to reduce angina symptoms and enhance exercise capacity with minimal side effects.

30 January 2023 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
AHAli Mohammad Haji-Zeinali
Ali Mohammad Haji-Zeinali
PMPejman Mansouri
Pejman Mansouri
NHNeda Raeis Hosseini
Neda Raeis Hosseini
KAKiomars Abbasi
Kiomars Abbasi
MSMahamoud Shirzad
Mahamoud Shirzad
MHMohammad Mohsen Haji-Zeinali
Mohammad Mohsen Haji-Zeinali

16 December 2022 in Medicine
Verified
Journal Article
Open access
FMFatemeh Majidi
Fatemeh Majidi
ARAbbas Mohagheghi Dare Ranj
Abbas Mohagheghi Dare Ranj
MJMana Jameie
Mana Jameie
MJMelika Jameie
Melika Jameie
PMPejman Mansouri
Pejman Mansouri
SSShahin Shirani
Shahin Shirani
Cardiovascular injuries induced by SARS CoV-2 have been reported repeatedly in various studies. Therefore, it is necessary to understand cardiac complications at a low cost, quickly. This study aimed to determine the relationship between cardiological parameters and polymerase chain reaction (PCR) in patients with coronavirus infection. : Patients who were admitted to the emergency department due to the ongoing pandemic, all patients with similar symptoms to coronavirus disease 2019 infection were initially admitted to the respiratory emergency room and underwent subsequent evaluations to confirm or rule out SARS-COV2 infection symptoms were assessed for eligibility. Patient were categorized into 2 groups 1. Positive PCR and negative PCR groups. Binary logistic regression was performed to assess the effect of several factors on the likelihood of developing positive troponin, reduced ejection fraction (EF), and Positive brain natriuretic peptide (BNP). Among 195 patients included, 115 (58.9%) had positive PCR. Patient in the positive PCR and negative PCR were 58.04 ± 18.03 and 59.19 ± 15.38 years of age, respectively. Patients in the “positive PCR” were significantly less likely to have chronic kidney disease (6.69% vs 17.5%, P value: .022), consume calcium channel blockers (6.69% vs 18.75%, P value:0.012). At the univariable level, positive PCR was significantly associated with fewer odds for positive BNP (OR:0.46, P = .019); nevertheless, the association was no longer significant after adjusting for confounders (adjusted OR:0.56, P = .158). Unadjusted positive PCR results were not found to have a significant association with positive troponin or reduced EF. Likewise, multivariable regression revealed no association between positive PCR and positive troponin (aOR:1.28, P = .529) and reduced EF (aOR:0.65, P = .369). PCR positivity did not result in positive troponin and BNP and did not appear to decrease EF. In other words, serial troponin and BNP checks and initial echocardiography in coronavirus disease 2019 respiratory emergencies do not make significant differences in diagnostic and therapeutic management and inpatient outcomes of patients with positive or negative PCR and are not specific findings. Evidence suggests some coronavirus-induced cardiac complications will be manifested in the long term.

31 August 2022 in Toxics
Verified
Journal Article
Open access
PDF file
RBRoya Sattarzadeh Badkoubeh
Roya Sattarzadeh Badkoubeh
MFMostafa Farajpour
Mostafa Farajpour
MSMohammadreza Salehi
Mohammadreza Salehi
ASAlborz Sherafati
Alborz Sherafati
ZZZahra Zamani
Zahra Zamani
ASAkram Sardari
Akram Sardari
Echinocandins selectively inhibit fungal cell wall synthesis and, therefore, have few side effects. However, there are reports of hemodynamic and cardiac complications. We conducted this study to investigate the effects of caspofungin both on the noninvasive echocardiographic indices of myocardial function and myocardial injury based on serum high-sensitivity cardiac troponin I (hs-cTnI) levels. This study was conducted on patients treated for candidemia. The hs-cTnI level and echocardiographic parameters were measured before and 1 h after the infusion of the induction dose of caspofungin. Data were compared between central and peripheral venous drug administration routes. Fifteen patients were enrolled in the study. There were no significant differences in the echocardiographic parameters between the baseline and post-treatment period. The mean hs-cTnI level exhibited a significant rise following drug administration (0.24 ± 0.2 ng/mL vs 0.32 ± 0.3 ng/mL; p = 0.006). There was also a significant difference concerning the hs-cTnI level between central and peripheral venous drug administration routes (p = 0.034). Due to differences in the hs-cTnI level, it appears that the administration of caspofungin may be associated with myocardial injury. Our findings also showed a higher possibility of cardiotoxicity via the central venous administration route.

1 January 2019
Verified
Journal Article
Closed access
ANArvin Najafi
Arvin Najafi
ABAbolfazl Bagherifard
Abolfazl Bagherifard
MKMohammad H. Kaseb
Mohammad H. Kaseb
SMSeyed Mohammad Javad Mortazavi
Seyed Mohammad Javad Mortazavi
PMPejman Mansouri
Pejman Mansouri